The present disclosure provides composition having at least one leuco composition conforming to Formula (I):
Ar.sup.1Ar.sup.2Ar.sup.3CH(I)
wherein Ar.sup.2 and Ar.sup.3 are independently a carbocyclic aryl or heteroaryl, and Ar.sup.1 is selected from the group consisting of: unsubstituted phenyl, electron deficient carbocyclic aryl, and heteroaryl. The present disclosure also provides a method of detecting an authentic composition and test kits for detecting authentic compositions.

The present invention relates to the use of iminooxothiazolidine derivatives for preventing or treating hair growth disorders. The iminooxothiazolidine derivatives may be formulated as compositions suitable for either the systemic administration or the local application to the scalp.

The invention relates to the use of an agent and a composition, respectively, comprising the following active ingredients: a) an aromatase inhibitor and/or a 5--reductase inhibitor, b) an antioxidant, and c) hyaluronic acid for cosmetic purposes.

Provided is a composite containing bio-active material stably combined with a rare-earth hydroxide compound having a layered structure. The bio-active materials in the composite are preserved in terms of long-term stability at high temperature of 50 C. or above and the composite maintained in the neutral pH condition to minimize side effects like latent toxicity, irritations, etc. Further, the present invention is useful for a skin-whitening, anti-wrinkle, or anti-aging cosmetic composition containing the composite.

A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.

The present invention provides compounds as PPAR agonists and their application, involving a new class of peroxisome proliferator-activated receptor (PPAR) gamma receptor agonist, which can inhibit the production of mitochondrial reactive oxygen species, and most of which can readily cross the blood-brain barrier. The present invention also includes pharmaceutical uses of the compounds.

A cooling agent composition contains a 2,2,6-trimethylcyclohexanecarboxylic acid derivative represented by the following general formula (1). The symbol * represents an asymmetric carbon atom. X represents NH, N(ZAr.sup.2), O or S, Z represents a single bond or an alkylene group having 1 to 3 carbon atoms which may have a substituent, Ar.sup.2 represents an aryl group having 6 to 20 carbon atoms which may have a substituent or an aromatic heterocyclic group having 2 to 15 carbon atoms which may have a substituent. Y each independently represents a methylene group which may have a substituent, and n represents an integer of 0 to 3. Ar.sup.1 represents an aryl group having 6 to 20 carbon atoms which may have a substituent or an aromatic heterocyclic group having 2 to 15 carbon atoms which may have a substituent.

##STR00001##

The present disclosure relates to compounds, cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or or wrinkles of skin comprising application of the compounds or compositions disclosed.

The invention relates primarily to a method of modulation, preferably of in vitro and/or in vivo modulation, of the cold menthol receptor TRPM8, wherein the receptor is contacted with at least one modulator selected from the group consisting of the compounds of the structure type 1 described herein. The present invention further relates to corresponding uses and compositions comprising such compounds.

A personal care composition is provided, comprising: a vehicle; a surfactant; a water-soluble cellulose ether base material substituted with a hydrophobic group having a carbon chain with 8 to 15 carbon atoms; wherein the water-soluble cellulose ether base material has a weight average molecular weight, M.sub.w, of >800,000 Daltons; and, wherein the body wash formulation contains <0.01 wt % alkyl sulfate and <0.01 wt % alkyl ether sulfate.